The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: Interim safety and survival data on 65 patients
Open accessAbstract
Hepatocellular carcinoma (HCC) generally arises in a cirrhotic liver and, in most cases, is multifocal and bilobar. Although trans-hepatic artery chemoembolization (TACE) can be highly affective in shrinking tumors, it is limited by virtue of the damage that it can cause to the liver that is already damaged by chronic disease. A high priority in HCC research, after primary prevention and early detection, is to find new treatment modalities that are both effective and non-toxic to the underlying cirrhotic liver. A cohort of 65 patients with biopsy-proven unresectable HCC have been treated with hepatic arterial 90 Yttrium microspheres (Therasphere), and the interim results are reported here. Only 1 cycle of Therasphere treatment ever was performed on 46 patients, 17 patients had 2 cycles, and 2 patients had 3 cycles of therapy. The median dose delivered was 134 Gy, typically as either 5 or 10 GBq (2-4 million microspheres). Clinical toxicities include 9 episodes of abdominal pain and 2 episodes of acute cholecystitis, requiring cholecystectomy. A main lab toxicity was elevated bilirubin which increased by more than 200 % in 25 patients (30.5 %) during 6 months of therapy, although 18 of these patients had only transient elevation. A prominent finding was prolonged and profound (> 70%) lymphopenia in more than 75% of the patients, but without clinical significance. Forty-two patients (64.6%) had a substantial decrease in tumor vascularity in response to therapy, and 25 patients (38.4%) had a partial response, by computed tomography scan. Median survival for Okuda stage I patients (n = 42) was 649 days (historical comparison 244) and for Okuda stage II patients (n = 23) was 302 days (historical comparison 64 days). All patients were followed after therapy for a minimum of 6 months. There were 42 deaths, 21 due to liver failure, 6 from HCC progression, and 3 from metastases. Therasphere appears to be a relatively safe and effective therapy for advanced-stage unresectable HCC. (Liver Transpl 2004;10:S107-S110.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres.
Dancey, J. E., Shepherd, F. A., Paul, K., et al. (2000) · PubMed · Cited by 295
Andrews, J. C., Walker, S., Ackermann, R. J., Cotton, L., Ensminger, W. D., & Shapiro, B. (1994) · PubMed · Cited by 261
Hepatocellular carcinoma: pilot trial of treatment with Y-90 microspheres.
Houle, S., YIP, T.-C. K., Shepherd, F. A., ROTSTEIN, L. E., Sniderman, K. W., Theis, E., Cawthorn, R. H., & Richmond-Cox, K. (1989) · Radiology · doi:10.1148/radiology.172.3.2549567 · Cited by 157
Hepatic malignancies: improved treatment with intraarterial Y-90.
Herba, M. J., Illescas, F. F., Thirlwell, M. P., Boos, G. J., Rosenthall, L., Atri, M., & Bret, P. (1988) · Radiology · doi:10.1148/radiology.169.2.3174978 · Cited by 144
Steel, J. L., Baum, A. E., & Carr, B. I. (2003) · Psycho-Oncology · doi:10.1002/pon.725 · Cited by 86
Self-citation
Cited by
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Kennedy, A., Nag, S., Salem, R., Murthy, R., McEwan, A. J., Nutting, C., Benson, A., Espat, J., Bilbao, J. I., Sharma, R. A., et al. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.11.060 · Cited by 676
Sangro, B., Carpanese, L., Cianni, R., Golfieri, R., Gasparini, D., Ezziddin, S., Paprottka, P. M., Fiore, F., Van Buskirk, M., Bilbao, J. I., et al. (2011) · Hepatology · doi:10.1002/hep.24451 · Cited by 652
Auger electrons for cancer therapy – a review
Ku, A., Facca, V. J., Cai, Z., & Reilly, R. M. (2019) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-019-0075-2 · Cited by 643
Kulik, L. M., Carr, B. I., Mulcahy, M. F., Lewandowski, R. J., Atassi, B., Ryu, R. K., Sato, K. T., Benson, A., Nemcek, A. A., Gates, V. L., et al. (2008) · Hepatology · doi:10.1002/hep.21980 · Cited by 620
Self-citationSalem, R., Lewandowski, R. J., Atassi, B., Gordon, S. C., Gates, V. L., Barakat, O., Sergie, Z., Wong, C.-Y. O., & Thurston, K. G. (2005) · Journal of Vascular and Interventional Radiology · doi:10.1097/01.rvi.0000184594.01661.81 · Cited by 404
Liver disease induced by radioembolization of liver tumors: Description and possible risk factors
Sangro, B., Gil‐Alzugaray, B., Rodriguez, J., Sola, I., Martinez‐Cuesta, A., Viudez, A., Chopitea, A., Iñarrairaegui, M., Arbizu, J., & Bilbao, J. I. (2008) · Cancer · doi:10.1002/cncr.23339 · Cited by 369
Kulik, L. M., Atassi, B., van Holsbeeck, L., Souman, T., Lewandowski, R. J., Mulcahy, M. F., Hunter, R. D., Nemcek, A. A., Abecassis, M. M., Haines, K. G., et al. (2006) · Journal of Surgical Oncology · doi:10.1002/jso.20609 · Cited by 333
Radioembolization for hepatocellular carcinoma
Sangro, B., Iñarrairaegui, M., & Bilbao, J. I. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.07.012 · Cited by 315
Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer
Hamoudeh, M., Kamleh, M. A., Diab, R., & Fessi, H. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.013 · Cited by 283
Review article: the management of hepatocellular carcinoma
CABRERA, R., & NELSON, D. R. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04200.x · Cited by 222
Metadata
- Authors
- Carr, B. I.
- Venue
- Liver Transplantation
- Published
- 2004-02
- Volume
- 10
- Issue
- Supplement 2
- Pages
- S107-S110
- ISSN
- 1527-6465 (ISSN-L)
- OpenAlex
- W2010047598
- Cited by
- 261
- References
- 5
- FWCI
- 12.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.